|
Price: $32.9200
$2.50 
8.218%
|
| Day's High:
| $32.95
| Week Perf:
| 13.2 %
|
| Day's Low: |
$ 30.90 |
30 Day Perf: |
5.55 % |
| Volume (M): |
766 |
52 Wk High: |
$ 33.33 |
| Volume (M$): |
$ 25,230 |
52 Wk Avg: |
$23.98 |
| Open: |
$31.04 |
52 Wk Low: |
$18.61 |
|
|
| Market Capitalization (Millions $) |
2,540 |
| Shares
Outstanding (Millions) |
77 |
| Employees |
677 |
| Revenues (TTM) (Millions $) |
390 |
| Net Income (TTM) (Millions $) |
-54 |
| Cash Flow (TTM) (Millions $) |
90 |
| Capital Exp. (TTM) (Millions $) |
10 |
Veracyte Inc
Veracyte Inc. is a leading genomic diagnostics company that provides solutions to patients who suffer from thyroid and lung diseases, as well as other types of cancer. The company is headquartered in South San Francisco, California, and has additional offices in Austin, Texas, and Italy.
Veracyte is focused on developing and commercializing genomic tests that enable doctors to diagnose and monitor patients with complex diseases more accurately. The company's products are based on RNA sequencing technology and genomic analysis, which help provide more precise information about the underlying genetic causes of disease.
Veracyte's flagship product, the Afirma Thyroid FNA Analysis, is used to diagnose thyroid nodules, which are a common medical problem that often requires further investigation to determine if they are benign or malignant. The Afirma Thyroid FNA Analysis delivers a diagnostic yield of up to 95%, allowing for more accurate diagnoses and reducing the number of unnecessary surgeries.
In addition to its thyroid diagnostic product, Veracyte also offers a lung cancer diagnostic test called the Percepta Bronchial Genomic Classifier. This test is used to diagnose early-stage lung cancer in patients who have received inconclusive biopsy results. It uses genomic analysis to identify the presence of cancer cells in the lungs, enabling doctors to start treatment at an earlier stage.
Veracyte's genomic testing products have won multiple awards and have been validated by leading medical institutions, such as the MD Anderson Cancer Center and the National Cancer Institute. The company has also secured partnerships with large pharmaceutical companies, such as Roche, to develop diagnostic tests for a wide range of diseases.
Along with its focus on developing genomic tests, Veracyte is also committed to advancing the field of genomic medicine through research and collaborations with academic institutions. The company has published numerous scientific papers and presented findings at major industry conferences.
Veracyte has a strong financial position, with significant revenues and ongoing growth. The company's market cap surpasses $3 billion, and its stock enjoys a consistently solid investor following. Its leadership team comprises experienced executives and key opinion leaders appointed from top-tier organizations to ensure consistent quality results and steady progress.
overall, Veracyte is seen an innovative, reliable, and valuable partner for patients and practitioners seeking more accurate diagnostic tools based on genomic technology.
Company Address: 6000 Shoreline Court South San Francisco 94080 CA
Company Phone Number: 243-6300 Stock Exchange / Ticker: NASDAQ VCYT
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Veracyte Inc
Veracyte Inc (Nasdaq: VCYT) has reported its financial results for the first quarter ended March 31, 2024, showing significant improvement in key financial metrics compared to the same period last year. The company experienced a decrease in loss per share, from $-0.11 in the prior year to $-0.02 in the current fiscal span. Additionally, income per share improved from $-0.38 to an undisclosed figure, signaling a positive trend in the company's financial performance.
One of the most notable highlights from Veracyte's financial report was the substantial increase in revenue, which jumped by 17.498% to $96.84 million from $82.42 million in the same reporting season a year prior. However, the revenue did show a slight sequential decrease of -1.38% from $98.20 million. Despite this, the company still reported a net loss of $-1.864 million for the January to March 31, 2024 fiscal span, which was a significant improvement from the $-8.091 million loss in the same period last year.
|
| Veracyte Inc
Veracyte Inc (VCYT) is a company that has recently experienced significant growth in its revenue. In the Dec 31, 2023 report, the company announced a surge in revenue by 22.295% to $98.20 million compared to the similar quarter a year ago. This highlights the company's ability to generate more sales and increase its market share.
However, it is important to note that Veracyte Inc has also seen its deficit expand at $-0.38 per share. It is crucial to analyze the reasons behind this deficit and whether it is a temporary setback or a long-term concern. Sequentially, the company seems to be improving, as its EPS has improved from $-0.41 per share and revenue has advanced by 8.979% from $90.11 million.
During the October to December 31, 2023 financial period, Veracyte Inc realized a net deficit of $-28.293 million, which is larger than the deficit of $-3.844 million a year ago. It is important to dig deeper into the reasons behind this increased deficit and assess whether it is a result of strategic investments or operational inefficiencies.
|
| Veracyte Inc
Veracyte Inc, a prominent player in the Medical Laboratories industry, recently released its July to September 2023 fiscal results. While the company witnessed significant revenue growth, there are concerns regarding increasing deficits, inventory levels, and declining accounts receivable. In this article, we will analyze the implications of these results and speculate on how they might impact Veracyte Inc in the future.
Increasing Deficits:
One of the most alarming aspects of Veracyte Inc's financial results is the widening deficit per share. In the third quarter of 2023, the deficit per share stood at $-0.41, compared to $-0.12 in the same period last year. Additionally, the deficit increased from $-0.12 per share from the previous reporting period. This trend raises questions about Veracyte Inc's ability to manage its expenses effectively and control costs. The company needs to address these issues promptly to avoid negative long-term consequences.
|
| Veracyte Inc
Veracyte Inc, a Medical Laboratories company, recently released its financial report for the period ending on June 30, 2023. The report revealed a significant surge in revenue by 23.96% to $90.32 million compared to the same period a year ago. However, the company reported a net loss of $-8.402 million, resulting in a loss per share of $-0.12. This represents a slight increase in the loss per share from the previous reporting period, where it stood at $-0.11.
Despite the increased loss, there is still positive news for Veracyte Inc. The company managed to reduce its deficit compared to the same reporting season a year ago, which amounted to $-9.532 million. This reduction may indicate progress in addressing financial challenges and improving overall performance.
|
| Veracyte Inc
Veracyte Inc, a healthcare company that specializes in genomic diagnostics, has reported a significant surge in revenue by 21.597% to $82.42 million in the fiscal period ending March 31, 2023, compared to the same quarter the previous year. However, despite the impressive growth in revenue, Veracyte Inc has reported a net loss of $-8.091 million, or $-0.11 per share.
This is a considerable increase from the previous quarter, where the deficit was $-0.05 per share, and the revenue surge was only 2.646%, with a revenue of $80.30 million. The cumulative net loss for the company during the 12-month period ending with the first quarter of 2023 is $-30 million, resulting in a negative return on assets (ROA) of -2.63%.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.74 $ |
| Revenues (TTM) |
5.06 $
|
| Cash Flow (TTM) |
1.17 $ |
| Cash |
3.06 $
|
| Book Value |
14.68 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.74 $
|
| Revenues (TTM) |
5.06 $ |
| Cash Flow (TTM) |
1.17 $ |
| Cash |
3.06 $
|
| Book Value |
14.68 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
